The increasing adoption of telomere performance programs for leading a healthy life; growing focus on increasing healthy life expectancy (HALE); increasing government focus towards preventive healthcare; rising geriatric population and the subsequent growth in the need for cellular health screening; increasing research activities; growing adoption of the direct-to-consumer approach for the availability of kits; and increasing burden of chronic diseases.
The global Cellular Health Testing market size is projected to reach USD 3.42 billion by 2022 from USD 2.12 billion in 2017, at a CAGR of 10.0%.
Genova Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Quest Diagnostics (U.S.), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany), DNA Labs (India), and Cleveland HeartLab, Inc. (U.S.) are some key players in this market. These companies are focusing on increasing their presence in the high-growth markets through both organic as well as inorganic growth strategies such as product launches, acquisitions, and expansions.
For More Details, Download a PDF Brochure:-
“In 2016, Telomere Diagnostics accounted for the largest share of the cellular health screening market”
With its large presence and expertise in telomere testing, the company has maintained its leadership position in the market. Telomere majorly focuses on developing new products that offer innovative solutions to help people test their cellular health and take preventive and therapeutic measures as required. For instance, in 2016, the company launched the TeloYears genetic test, which helps track the cellular age of an individual based on the telomere length.
“Life Length has maintained its strong market position by dominating the European telomere testing market”
The company has adopted various strategies, such as partnerships, agreements, and joint ventures, to sustain its growth in the telomere testing market. For instance, the company partnered with Eastern Biotech & Life Sciences (Dubai) in 2016 and Freiburg Medical Laboratory Middle East (FML) (Dubai) in 2014 to expand its business in the Middle East. Also, in 2014, the company signed an agreement with Invivo Clinical (U.K.) to offer its telomere analysis technology (TAT) in the U.K.
We can help with your specific research requirement for this market. Please share your specific interest to help us serve you better, Request Sample Pages:-